EOCN

Eocene Ltd.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$2.39

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %22.2 / %30

Non-compliant assets / Total market cap %184.8 / %30

Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.

Website

Analysis (Turkish): EOCN Hissesi Caiz mi, Helal mi? Eocene Ltd. Katılım Analizi